Navigation Links
Three Firms, Two Training Programs Garner Greater Baltimore Committee's 2009 Bioscience Awards
Date:3/12/2009

BALTIMORE, March 12 /PRNewswire-USNewswire/ -- Maryland biotech CEOs and companies were honored today by the Greater Baltimore Committee as winners of the region's fourth bioscience award competition.

Winners of the 2009 Bioscience Awards are:

  • Best New Product or Progress: C. Randal Mills, Ph.D., president and CEO, Osiris Therapeutics, Inc. Mills' Columbia-based company has spent more than $300 million developing stem cell therapies. The funding has allowed Osiris to complete clinical trials necessary to demonstrate the safety and efficacy of two next-generation stem cell treatments for serious conditions such as graft versus host disease, Crohn's disease, arthritis, diabetes, pulmonary disease and heart attacks.
  • Leadership in Bioscience Award: Karen Olsen, CEO, BioMarker Strategies, LLC. Olsen's tissue-based cancer diagnostics company is based at the Science + Technology Park at Johns Hopkins. BioMarker Strategies is developing live cell biomarker tests for solid-tumor based cancers.
  • Entrepreneurial Spirit Award: Suzanne Sysko Clough, M.D., founder and chief medical officer, WellDoc Communications, Inc. Clough's Baltimore-based health care company develops technology-based solutions to improve diabetes outcomes and reduce health care costs. Since founded, WellDoc successfully raised more than $6 million in angel funding and is moving forward with a 300 patient trial sponsored by leaders in telecommunications, medical device, and health insurance provider industries.
  • President's Award:
    1. Ellen Hemmerly, executive director, bwtech@UMBC Research & Technology Park, co-principal investigator for NSF Grant, coordinator of incubation operations for ACTiVATE and ACTiVATE Leadership Team. ACTiVATE(R) is a year-long program to train women with significant technical or bus
      '/>"/>

SOURCE Greater Baltimore Committee
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST
2. Savara Expands Board of Directors, Appoints Three New Members
3. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
4. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
5. LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates
6. ViroPharma to Present at Three November Healthcare Conferences
7. Gable PR Honored by PRSA San Diego Chapter with Three Awards for Client Programs
8. NicOx Reports Results for the First Three Quarters of 2008
9. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
10. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Pinnacle Biologics, a,private, full-service pharmaceutical and biotech ... agreement with pharmexx to expand sales,support activities in ... of the,agreement were not disclosed., Viren Grover, ... to conclude this agreement with pharmexx, which allows ...
... ON, July 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and six months ended May 31, 2008. All dollar ... At May 31, 2008, our cash and cash ... 29, 2008., The net loss for the second ...
... Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, ... V(TM) USA post-approval study, with six,hospital centers already recruiting and enrolling ... the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA ...
Cached Biology Technology:Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/29/2014)... academics in the University of Bristol,s Nutrition and Behaviour ... calories into account when planning meals. , The research, ... of Ingestive Behavior Conference (SSIB 2014) in Seattle, USA ... we do. , The team was led by Professor ... Experimental Psychology. , As part of a Biotechnology and ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... BETHESDA, MD August 23, 2007 On August 16, the ... blood-thinner warfarin, sold under the brand name Coumadin. The new ... that may be safer for patients with variations in two ... through genetic testing, which may be a useful tool in ...
... Optics 2007 (FiO), the 91st Annual Meeting of the ... 16-20 in San Jose, Calif., alongside Laser Science XXIII, ... of Laser Science. Reporters interested in obtaining a ... at 202.416.1437, cmorri@osa.org . FiO RESEARCH ...
... system designed for brain tumor therapy has shown promising ... devised by University of Nottingham scientists. The project, conducted ... Human Development, will be featured in the September issue ... cancers is particularly difficult for a number of reasons, ...
Cached Biology News:American College of Medical Genetics responds to new FDA labeling decision for warfarin 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: